QIAGEN N.V. has entered into an agreement to purchase all outstanding shares of Shenzhen PG Biotech Co Ltd based in Shenzhen, China. PG Biotech is a leading developer, manufacturer and supplier of polymerase chain reaction (PCR)-based molecular diagnostic kits in China. The acquisition will expand QIAGEN's position as a leading provider of molecular Diagnostics solutions to OEM partners and customers in the rapidly growing Asian markets. Read more about the terms of the acquisition here.